Physician profile
Firas Qaqa
NPI 1659786606
$47,682.64
in general payments reported to CMS, 2019-2025
23 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $1,204 · 2021: $30K · 2022: $6,415 · 2023: $1,734 · 2024: $4,922 · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,186 · Travel and Lodging: $4,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,186.09 |
| Travel and Lodging | $4,502.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $31,563.75 | 2021-2025 | Corevalve Evolut R |
| Abbott Laboratories | $7,772.86 | 2019-2025 | Perclose Proglide, Supera, Esprit |
| Penumbra, INC. | $3,481.68 | 2022-2024 | Indigo System |
| Boston Scientific Corporation | $1,360.03 | 2022-2025 | Versacross Access Solution, Varithena Administration Pack, Watchman |
| Philips North America LLC | $957.81 | 2022-2023 | |
| Abiomed | $724.46 | 2022-2025 | Impella |
| Cardiovascular Systems INC. | $515.81 | 2021-2022 | |
| Shockwave Medical, INC | $407.40 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $200.13 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $157.91 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.80 | 2019-2021 | |
| Cardiva Medical, INC. | $76.04 | 2022 | |
| Angiodynamics, INC. | $42.69 | 2024 | Auryon Laser System 100-120 Vac |
| Novartis Pharmaceuticals Corporation | $32.83 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $31.61 | 2025 | Paradise Ultrasound Renal Denervation System |
| Tactile Systems Technology INC | $30.22 | 2024 | Flexitouch Plus, Entre Plus |
| Terumo Medical Corporation | $28.90 | 2025 | Navicross |
| Pfizer INC. | $26.25 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $16.57 | 2019 | |
| Merck Sharp & Dohme LLC | $15.58 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2021 | |
| Gilead Sciences, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Qaqa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.